- The disease
- Tendons are the fibrous tissues that connect muscle to bone, and tendon injuries — particularly to the rotator cuff in the shoulder and the Achilles tendon — are among the most common musculoskeletal conditions requiring surgical intervention. Damaged tendons have limited natural healing capacity, and a significant proportion of surgically repaired tendons re-tear over time. Current standard-of-care repair techniques rely on suturing or grafting, without a biological component aimed at enhancing the quality of new tissue formed. There is no cell-based therapy currently approved in Australia or the United States specifically for tendon repair.
- What the asset is trying to do
- TendinoGen is an autologous tenocyte therapy, meaning cells are harvested from the patient's own tendon tissue, expanded in a laboratory to increase their number, and then re-implanted at the repair site during surgery. Tenocytes are the primary cell type responsible for producing and maintaining the structural proteins that give tendons their strength and flexibility. This approach differs from standard surgical repair, which does not introduce additional biological material to promote tissue regeneration, and from platelet-rich plasma or growth-factor injections, which do not deliver live tendon-specific cells. The regenerative_biologic class reflects that the product is a living cell preparation rather than a small molecule or conventional biologic such as a monoclonal antibody.
- Efficacy benchmarks in this setting
- In the context of rotator cuff repair — a commonly studied tendon indication — published data on standard surgical repair alone have shown re-tear rates ranging broadly depending on tear size and patient factors, with some studies reporting re-tear in a substantial proportion of patients over multi-year follow-up (specific figures vary by study and are not cited here without a named source available in the input data). For Achilles tendon repair, comparative benchmark data. No cell-based autologous tenocyte therapy is currently approved by any major regulator, so there is no approved-product benchmark efficacy figure available for direct comparison. Any early-stage or interim figures reported for TendinoGen are not statistically comparable to data from controlled pivotal trials of approved therapies.
- Commercial context
- Orthocell has disclosed first sales of its Remplir product in the Canadian market, which it described as a US$75 million market, in an ASX announcement dated 29 April 2026. A separate ASX announcement dated 27 April 2026 referenced a 90% success rate for Remplir in a real-world study; Remplir is a distinct nerve repair product and is not TendinoGen. No regulatory approval for TendinoGen has been disclosed in the available announcements. TendinoGen is described by the company as a Phase 3 asset; its status as the company's lead asset relative to Remplir and other pipeline products is based on available disclosure. No partnership, licensing, or manufacturing deal specific to TendinoGen has been disclosed in the announcements provided.